Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes for systemic therapy in women with ovarian cancer.
Elit L, Chartier C, Oza A, Hirte H, Levine M, Paszat L. Elit L, et al. Among authors: oza a. Gynecol Oncol. 2006 Nov;103(2):554-8. doi: 10.1016/j.ygyno.2006.03.052. Epub 2006 May 24. Gynecol Oncol. 2006. PMID: 16725183
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B. Moore M, et al. Among authors: oza a. Ann Oncol. 2005 Oct;16(10):1688-94. doi: 10.1093/annonc/mdi310. Epub 2005 Jul 8. Ann Oncol. 2005. PMID: 16006586 Free article. Clinical Trial.
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
Ledermann JA, Embleton-Thirsk AC, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Oza A, Vaughan M, Friedlander M, González-Martín A, Deane E, Popoola B, Farrelly L, Swart AM, Kaplan RS, Parmar MKB; ICON6 collaborators. Ledermann JA, et al. Among authors: oza a. ESMO Open. 2021 Apr;6(2):100043. doi: 10.1016/j.esmoop.2020.100043. Epub 2021 Feb 18. ESMO Open. 2021. PMID: 33610123 Free PMC article. Clinical Trial.
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Hoskins P, et al. Among authors: oza a. J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56. doi: 10.1093/jnci/djq362. Epub 2010 Oct 11. J Natl Cancer Inst. 2010. PMID: 20937992 Free article. Clinical Trial.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. Among authors: oza am. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.
Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL. Duran I, et al. Among authors: oza a. Br J Cancer. 2006 Nov 6;95(9):1148-54. doi: 10.1038/sj.bjc.6603419. Epub 2006 Oct 10. Br J Cancer. 2006. PMID: 17031397 Free PMC article. Clinical Trial.
562 results